Company ProfileWe are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
|Recent Press Releases||More >>|
|09/28/16||Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society|
|CARLSBAD, Calif., Sept. 28, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Ionis Pharmaceuticals, Inc., has been awarded the Lifetime Achievement Award from the Oligonucleotide Therapeutics Society, OTS. The OTS Lifetime Achievement Award recognizes Dr. Crooke's lasting commitment to the field of oligonucleotide therapeutics through outstanding contributions to education, ... |
|09/26/16||Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy|
|Submission of Marketing Authorization Application to the European Medicines Agency Planned in the Coming Weeks
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) and Ionis (NASDAQ:IONS) today announced that Biogen has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of nusinersen, an investigational treatment for spinal muscular atrophy ... |
|09/22/16||Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease|
|CAMBRIDGE, Mass., Sept. 22, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the publication in The Lancet of key clinical results of two randomized, controlled studies of IONIS-APO(a)Rx and IONIS-APO(a)-LRx, the company's Lp(a)-lowering drugs designed to treat cardiovascular disease and aortic valve stenosis. Lipoprotein(a), or Lp(a), is an independent, causal, genetic risk factor for cardiovascular disease and ao... |
|09/15/16||Akcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome|
|--Largest study conducted to date involving people living with FCS--
--Findings to be presented during American Society for Preventative Cardiology Congress--
Sept. 15, 2016
/PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of
Ionis Pharmaceuticals, Inc.
(NASDAQ: IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced ... |
|There are currently no events scheduled.|
For more information requests, please visit our Information Request page.
If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.
Data provided by Nasdaq. Minimum 15 minutes delayed.